Amgen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovation since its founding in 1980. With a strong presence in major operational regions including Europe and Asia, Amgen focuses on developing therapies in areas such as oncology, nephrology, and inflammation. Renowned for its pioneering biologic medicines, Amgen's core products include Enbrel, Neulasta, and Prolia, which are distinguished by their ability to target specific disease pathways effectively. The company has achieved significant milestones, including the introduction of the first recombinant human erythropoietin, Epogen, which transformed the treatment of anaemia. As a prominent player in the biotechnology industry, Amgen continues to excel, holding a strong market position and receiving numerous accolades for its commitment to scientific excellence and patient care.
How does Amgen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Amgen's score of 62 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Amgen reported total carbon emissions of approximately 1,650,000,000 kg CO2e, comprising Scope 1 emissions of about 153,000,000 kg CO2e and Scope 2 emissions of around 12,000,000 kg CO2e. The company has set ambitious targets to achieve carbon neutrality for its owned and operated facilities by 2027, covering both Scope 1 and Scope 2 emissions. As part of its commitment, Amgen aims to increase its sourcing of renewable electricity from 29% in 2019 to 100% by 2027, with a continued commitment to maintain this level through 2030. Amgen has made significant progress towards its reduction goals, achieving 54% of its targeted reductions for Scope 1 and 2 emissions by 2023, based on a 2019 baseline. The company is also focused on engaging its suppliers, with a target that 73% of its suppliers by spend will have science-based targets by 2027. Overall, Amgen's climate commitments reflect a strong dedication to reducing greenhouse gas emissions and transitioning to renewable energy sources, aligning with industry standards for sustainability and climate action.
Access structured emissions data, company-specific emission factors, and source documents
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 144,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amgen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.